Current and Emerging Treatments in the Management of Castration-Resistant Prostate Cancer

David Shapiro; Basir Tareen


Expert Rev Anticancer Ther. 2012;12(7):951-964. 

In This Article


Prostate cancer is the second most common cause of death in American men, and a great majority of those men die with CRPC. There are currently four new agents approved in the USA for use in CRPC: cabazitaxel, AA, sipuleucel-T and denosumab. While the current first line treatments are docetaxel and sipuleucel-T, ongoing and future clinical trials of these new agents, different docetaxel regimens, and emerging and experimental agents aimed at novel targets will lead to changes in the current treatment algorithm outlined in this review.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.